CN1973051A - 用于预测对氯氮平治疗的应答性的生物标记 - Google Patents

用于预测对氯氮平治疗的应答性的生物标记 Download PDF

Info

Publication number
CN1973051A
CN1973051A CNA2005800178554A CN200580017855A CN1973051A CN 1973051 A CN1973051 A CN 1973051A CN A2005800178554 A CNA2005800178554 A CN A2005800178554A CN 200580017855 A CN200580017855 A CN 200580017855A CN 1973051 A CN1973051 A CN 1973051A
Authority
CN
China
Prior art keywords
slc6a3
patient
gene
polymorphism
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA2005800178554A
Other languages
English (en)
Chinese (zh)
Inventor
Y·何
E·M·勒罗伊
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis AG filed Critical Novartis AG
Publication of CN1973051A publication Critical patent/CN1973051A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/55131,4-Benzodiazepines, e.g. diazepam or clozapine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/106Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/156Polymorphic or mutational markers
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/158Expression markers
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/172Haplotypes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Pathology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CNA2005800178554A 2004-06-04 2005-06-03 用于预测对氯氮平治疗的应答性的生物标记 Pending CN1973051A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US57713104P 2004-06-04 2004-06-04
US60/577,131 2004-06-04

Publications (1)

Publication Number Publication Date
CN1973051A true CN1973051A (zh) 2007-05-30

Family

ID=34970966

Family Applications (1)

Application Number Title Priority Date Filing Date
CNA2005800178554A Pending CN1973051A (zh) 2004-06-04 2005-06-03 用于预测对氯氮平治疗的应答性的生物标记

Country Status (10)

Country Link
US (1) US20090281090A1 (https=)
EP (1) EP1756314A1 (https=)
JP (1) JP2008505060A (https=)
CN (1) CN1973051A (https=)
AU (1) AU2005250142B2 (https=)
BR (1) BRPI0510775A (https=)
CA (1) CA2568729A1 (https=)
MX (1) MXPA06014127A (https=)
RU (1) RU2006146207A (https=)
WO (1) WO2005118848A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008136995A1 (en) * 2007-04-30 2008-11-13 The Ohio State University Research Foundation Polymorphisms in genes affecting dopamine transporter disorders and uses thereof
US7932042B1 (en) 2010-10-13 2011-04-26 Suregene, Llc Methods and compositions for the treatment of psychotic disorders through the identification of the olanzapine poor response predictor genetic signature
WO2012167281A2 (en) * 2011-06-02 2012-12-06 Gareth Davies Clinical application utilizing genetic data for effective medication management
WO2014023852A1 (en) 2012-08-10 2014-02-13 Istituto Superiore di Sanità Biomarkers
CN112195230B (zh) * 2020-09-17 2022-08-23 青岛大学附属医院 一种用于氯氮平个体化用药指导的基因检测试剂、试剂盒、检测方法及应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2381525A (en) * 2001-11-01 2003-05-07 Tcs Cellworks Ltd Regulating gene expression
IL163645A0 (en) * 2002-02-21 2005-12-18 Idgene Pharmaceuticals Ltd Association of snps in the comt locus and neighboring loci with schizophrenia, bipolar disorder, breast cancer and colorectal cancer
AU2003231897A1 (en) * 2002-06-03 2003-12-19 Idgene Pharmaceuticals Ltd. Association of snps in the dgcr2 locus and neighboring loci with schizophrenia
WO2004074513A1 (en) * 2003-02-21 2004-09-02 Novartis Ag Methods for the prediction of suicidality during treatment

Also Published As

Publication number Publication date
MXPA06014127A (es) 2007-01-31
EP1756314A1 (en) 2007-02-28
BRPI0510775A (pt) 2007-11-20
AU2005250142A1 (en) 2005-12-15
AU2005250142B2 (en) 2008-08-21
RU2006146207A (ru) 2008-07-20
WO2005118848A1 (en) 2005-12-15
CA2568729A1 (en) 2005-12-15
JP2008505060A (ja) 2008-02-21
US20090281090A1 (en) 2009-11-12

Similar Documents

Publication Publication Date Title
US20100035251A1 (en) BioMarkers for the Progression of Alzheimer's Disease
CN109952383B (zh) 用于预测恩扎妥林活性的方法和组合物
CN1612941B (zh) 基于cntf基因的多态性治疗精神病和精神分裂症的方法
US20070065821A1 (en) Methods for the prediction of suicidality during treatment
JP2020089370A (ja) 抗精神病薬に基づく処置により誘導される錐体外路症状(eps)の発症を予測する方法
AU2005250142B2 (en) Biomarkers for the prediction of responsiveness to clozapine treatment
JP4979382B2 (ja) 薬剤誘発肝細胞毒性を予測するための遺伝子多型の使用
US20140045717A1 (en) Single Nucleotide Polymorphism Biomarkers for Diagnosing Autism
KR20070022710A (ko) 클로자핀 치료에 대한 반응성을 예측하기 위한 바이오마커

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication